Concepedia

Author

Aakanksha Khandelwal

University of Maryland, Baltimore

Also Known As

A Khandelwal, A. Khandelwal, Aakanksha Khandelwal, Aditya Khandelwal

21

Publications

829

Citations

12

H-Index

27

Concepts

All Affiliations

University of Maryland, BaltimoreUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer CenterUnited States Food and Drug Administration
AK

About

Aakanksha Khandelwal is an author at University of Maryland, Baltimore specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

410

2

Cell Biology

2

2

90

3

Natural Sciences

1

1

36

4

Biomolecular Engineering

1

1

36

5

Chemical Biology

1

1

36

Aakanksha Khandelwal

×

11

Publications

628

Citations

10

H-Index

YearCitations

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski,

Clinical Cancer Research

2012

207

Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1<i>H</i>-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer

Tadas S. Vasaitis, Aashvini Belosay, Adam Schayowitz,

Molecular Cancer Therapeutics

2008

134

Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts

Lalji K. Gediya, Aashvini Belosay, Aakanksha Khandelwal,

Bioorganic & Medicinal Chemistry

2007

50

Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data

Kerry L. Reynolds, Shaily Arora, Ravikumar Komandur Elayavilli,

Journal for ImmunoTherapy of Cancer

2021

42

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth

Jyoti Patel, Jhalak Mehta, Aashvini Belosay,

British Journal of Cancer

2007

40

Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent

Puranik Purushottamachar, Aakanksha Khandelwal, Tadas S. Vasaitis,

Bioorganic & Medicinal Chemistry

2008

39

Design, Synthesis, and Evaluation of Novel Mutual Prodrugs (Hybrid Drugs) of All-<i>trans</i>-Retinoic Acid and Histone Deacetylase Inhibitors with Enhanced Anticancer Activities in Breast and Prostate Cancer Cells in Vitro

Lalji K. Gediya, Aakanksha Khandelwal, Jyoti D. Patel,

Journal of Medicinal Chemistry

2008

36

First pharmacophore-based identification of androgen receptor down-regulating agents: Discovery of potent anti-prostate cancer agents

Puranik Purushottamachar, Aakanksha Khandelwal, Pankaj Chopra,

Bioorganic & Medicinal Chemistry

2007

28

A novel pro-oxidant combination of resveratrol and copper reduces transplant related toxicities in patients receiving high dose melphalan for multiple myeloma (RESCU 001)

Anshul Agarwal, Aakanksha Khandelwal, Kavita Pal,

PLoS ONE

2022

24

MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours

Aakanksha Khandelwal, Lalji K. Gediya, Vincent C.O. Njar

British Journal of Cancer

2008

18

Page 1